



(51) International Patent Classification:

C07D 471/04 (2006.01) **A61P 25/28** (2006.01)
A61K 31/519 (2006.01) **A61P 29/00** (2006.01)
A61P 9/00 (2006.01)

(21) International Application Number:

PCT/GB2011/051647

(22) International Filing Date:

2 September 2011 (02.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1014963.1 8 September 2010 (08.09.2010) GB
1101128.5 21 January 2011 (21.01.2011) GB

(71) Applicant (for all designated States except US): **UCB PHARMA S.A.** [BE/BE]; 60 Allée de la Recherche, B-1070 Brussels (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PARTON, Andrew Harry** [GB/GB]; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **ALI, Mezher Hussein** [GB/GB]; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **BROOKINGS, Daniel Christopher** [GB/GB]; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **BROWN, Julien Alistair** [GB/GB]; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **FORD, Daniel James** [GB/GB]; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **FRANKLIN, Richard Jeremy** [GB/GB]; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **LANGHAM, Barry John** [GB/GB]; UCB

Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **NEUSS, Judi Charlotte** [GB/GB]; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **QUINCEY, Joanna Rachel** [GB/GB]; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: **THOMPSON, John**; UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS

(57) Abstract: A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

